TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05962671
Drug: Opioid-sparing based anesthesia
Normalized name: Opioid anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative opioid-sparing maintenance comprised dexmedetomidine bolus dose of 1 mcg/kg followed by 0.3 mcg/kg/h, propofol 4-8 mg/kg/h and ketamine 25 mg/h for a max of 50 mg during the procedure, targeting bispectral index (BIS) between 45%-60%. The lean body weight will be used for calculation of the drugs.
Study: NCT06419582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo taken once daily for 21 days
Study: NCT06065449
Drug: Radiation Therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: standard 8 Gy delivered in a single fraction or 20 Gy delivered in 5 fractions~Arm 2: 16 Gy delivered in a single fraction or 27 Gy delivered in 3 fractions prescribed to planning target volume (PTV).
Study: NCT05198128
Drug: 0.9 % saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 % saline
Study: NCT05735197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo which has the same shape as Dapagliflozin but without active ingredient will be used as add on medication for control group.
Study: NCT05421923
Drug: SR1375 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single and multiple doses of SR1375 orally
Study: NCT05313828
Drug: Tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: tobramycin 4 times /day
Study: NCT06736990
Drug: CAL101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of CAL101 every 4 weeks over 24 weeks
Study: NCT06736990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusions of placebo every 4 weeks over 24 weeks
Study: NCT04820842
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching tablets.
Study: NCT05077527
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT06347003
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile normal saline (0.9% NaCl)
Study: NCT06417125
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were premedicated with normal saline 0.02 mL/kg in the holding area.
Study: NCT05371730
Drug: NCR300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of NK cells（NCR300）
Study: NCT05986877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05452564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to the placebo group will receive 2 mg oral daily placebo for ten weeks. Follow up visits will happen for both groups at weeks 1, 2, 4 and 10.
Study: NCT06510504
Drug: 225 mg BNC210
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg BNC210
Study: NCT06510504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06422117
Drug: HSK16149 20mg-40mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;
Study: NCT06422117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, oral, 2 capsules twice daily
Study: NCT04867057
Drug: Placebo for SAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to four dose ascending cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered orally as a single dose.
Study: NCT04867057
Drug: Trichomylin for MAD
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
Study: NCT04867057
Drug: Placebo for MAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy subjects meeting eligibility criteria were randomized to each dose cohort (up to three cohorts) to receive either Trichomylin or Placebo. The study drug (Trichomylin or Placebo) will be administered daily oral doses for a total of 9 days.
Study: NCT00299351
Drug: Depsipeptide
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05721144
Drug: Nitric Oxide Gas
Normalized name: Nitric oxide gas
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inspired NO/N2 will be delivered at 80 parts per million (ppm) after anesthesia induction and intubation and lasted until the end of surgery and leave the operating room.
Study: NCT05764122
Drug: BIIB131
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05764122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT05942612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection, single dose
Study: NCT05186285
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo.
Study: NCT03883360
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive a single daily dose of the oil vehicle used to dissolve CBD but without any active ingredient, in the same amount as the CBD group, for 12 weeks.
Study: NCT04308304
Drug: MK-1942
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1942 1 mg, 5 mg, and/or 10 mg capsules taken twice daily (BID) by mouth.
Study: NCT04308304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matched to MK-1942 taken BID by mouth.
Study: NCT05051995
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to the open-label placebo administration, an explanation why placebos without concealment might be effective is offered. Participants receive placebo pills with the instruction to take 2 pills daily for 2 weeks.
Study: NCT04551482
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 IU nasal spray, 4 times per day for 12 weeks
Study: NCT06680167
Drug: Spinal anesthesia (heavy bupivacaine 0.5%)
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5mg of Heavy bupivacaine 0.5% will be injected intrathecally for women undergoing elective caesarean section
Study: NCT06680167
Drug: spinal anesthesia (hyperbaric Prilocaine 2%)
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60mg of Hyperbaric Prilocaine 2% will be injected intrathecally for women undergoing elective caesarean section
Study: NCT06323161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo matched to cagrilintide and semaglutide subcutaneously.
Study: NCT05921058
Drug: Secretome
Normalized name: gonorrheal urethral secretion human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
Study: NCT05921058
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0,9% infusion
Study: NCT04768075
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion Simulator of Camrelizumab
Study: NCT06231758
Drug: Celecoxib 200mg
Normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain and help relieve symptoms of arthritis (eg, osteoarthritis, rheumatoid arthritis, or juvenile rheumatoid arthritis), such as inflammation, swelling, stiffness, and joint pain.
Study: NCT06556550
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: prescribed drug line
Study: NCT04679870
Drug: GB2064
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB2064 (formerly PAT-1251) is a high-affinity, selective, mechanism-based, small molecule inhibitor of LOXL2, administered twice a day
Study: NCT06525649
Drug: NPT 2042
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPT 2042 is a new drug being developed as an anti-seizure treatment.
Study: NCT06487416
Drug: Spiriva®Handihaler®
Approvals — FDA: no, EMA: no, PMDA: no
Description: By binding to M3 receptors, the action of acetylcholine is blocked to relieve spasm of bronchial smooth muscle.
Study: NCT05586971
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05152641
Drug: BGE-117, 4mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGE-117, 4mg Capsules
Study: NCT05152641
Drug: BGE-117, 12mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: BGE-117, 12mg Capsules
Study: NCT05991700
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consume 2 servings (30.66g/serving) per day for three days before cardiac surgery
Study: NCT06216886
Drug: OnabotulinumtoxinA 100 UNT [Botox]
Normalized name: onabotulinumtoxinA 100 UNT [Botox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injections will be placed in 25 unit aliquots allocated per affected trigeminal distribution. For example, if the target is the V1 territory, then the patient would get 25 units injected into the V1 distribution. This would be divided into 2.5 units per injection in 10 injection sites as outlined on the map. If V1/V2 were affected, the patient would get 50 units of onabotA. Maximum dose of 75 units if all three trigeminal distributions are involved. We have developed a specific map for administering the doses and this will be followed.
Study: NCT05411887
Drug: Rosuvastatin, Olmesartan Medoxomil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olostar Tablet
Study: NCT06012487
Drug: Low BPV Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each the patients' physician will invite patients to complete a 48-hour ABPM, then undergo cross-titration from their current antihypertensive regimen to a low BPV regimen, consisting of Amlodipine and Indapamide. Study staff will suggest to the treating physician to initially start patients on Amlodipine 5mg daily, with uptitration to 10mg daily to a goal systolic blood pressure (SBP)\<130 mmHg. Indapamide will be suggested to be added at 1.25mg daily and increased to 2.5mg daily, as needed to meet target SBP. Other antihypertensive medications will be suggested to be discontinued as the SBP target is reached. Patients not meeting target SBP on maximally tolerated Amlodipine and Indapamide will be suggested to have a long acting angiotensin-converting enzyme (ACE)/ angiotensin receptor blocker (ARB) added to their therapy. Patients will complete another 48-hour ABPM after 1 week at target SBP on the low-BPV regimen.
Study: NCT05641688
Drug: [18F]PI-2620
Approvals — FDA: no, EMA: no, PMDA: no
Description: The radioligand, \[18F\]PI-2620, will be injected intravenously at a dose of 185 MBq ± 20%
Study: NCT03847311
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: This group will receive supplies for 3 months of sugar pills three times a day for 3 months. Subjects will be asked to take their medications with every meal in addition to their regular pain medications.
Study: NCT06431256
Drug: Placebo HLD200 capsules
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses: 20mg capsules
Study: NCT06400511
Drug: Placebo Ophthalmic Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be applied twice a day to both eyelid margins.
Study: NCT05553314
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients randomized to placebo group will receive placebo.
Study: NCT06579092
Drug: AZD5004
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5004 film-coated tablet once daily during 36 weeks
Study: NCT06579092
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching AZD5004 film-coated tablet once daily during 36 weeks
Study: NCT06579105
Drug: Placebo (placebo matching AZD5004 film-coated tablet)
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo film-coated tablet (matching AZD5004)
Study: NCT06579105
Drug: AZD5004
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5004 film-coated tablet, once daily during 26 weeks
Study: NCT06033612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT05352178
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: gosereline 3.6 mg sc, leuproreline 7.5 mg sc, triptoreline 3.75 mg im Arm C: gosereline 3.6 mg sc 1x/month or gosereline 10.8 mg sc or leuproreline 7.5 mg sc 1x/month or leuproreline 45 mg sc or triptoreline 3.75 mg im 1x/month or triptoreline 11.5 mg im 1x/3months or triptoreline 22.5 mg im
Study: NCT05352178
Drug: Androgen receptor targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide
Study: NCT04748601
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qudexy XR Matching capsules
Study: NCT05934942
Drug: Yasmin®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol (EE) and Drospirenone (DRSP)
Study: NCT05027568
Drug: IOA-289
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral twice daily dosing of IOA-289
Study: NCT06511791
Drug: Placebo FE 999302
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active ingredient, subcutaneous injection.
Study: NCT05923099
Drug: LEO 138559
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEO 138559 given by injection just under the skin
Study: NCT05923099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given by injection just under the skin
Study: NCT06558643
Drug: MMV371 LAI
Normalized name: laidlomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-muscular dose
Study: NCT06558643
Drug: Placebo for MMV371
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intramuscular dose
Study: NCT06507371
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine: 1000mg/m2 d1-14 q3w
Study: NCT05375539
Drug: AGN-CognI.Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal dietary supplement products containing/based on AGN alcoholic extracts (including CognI.Q; Decursinol-50TM, GWB78®, Ache Action, Fast-Acting Joint Formula, EstroG-100/Profemin) are marketed in the US for memory enhancement, pain relief and for women's post-menopausal symptom management.
Study: NCT06186700
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will take chemotherapy cycle comprised intravenous Doxorubicin 60 mg/m²/cycle with intravenous Cyclophosphamide 600 mg/m²/cycle for four cycles, followed by weekly paclitaxel or dose-dense paclitaxel.
Study: NCT05622968
Drug: Intravaginal prostaglandin E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insertion of intravaginal Dinoprostone
Study: NCT06398808
Drug: Arm1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYIL1 capsules 25 mg for oral administration + 50 mg placebo
Study: NCT06398808
Drug: Arm 2
Normalized name: Surgitube Arm 2 5/8x50"
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZYIL1 capsules 50 mg for oral administration + 25 mg placebo
Study: NCT05761301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by subcutaneous (SC) injection.
Study: NCT04735393
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution administered for six weeks (QID for four weeks then BID for two weeks).
Study: NCT04735393
Drug: Placebo Comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle Ophthalmic Solution administered for one year (QID for four weeks then BID for 11 months).
Study: NCT05852431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT05749822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet/ day
Study: NCT05348785
Drug: BIIB122
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05348785
Drug: BIIB122-Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT05016349
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the approved standard therapy tamoxifen
Study: NCT04956926
Drug: JS201
Normalized name: Janus Kinase 2 (JAK2) Inhibitor JS201
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS201 is administered intravenously Q3W at the corresponding dose.
Study: NCT04936971
Drug: Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Switch from Mycophenolate Mofetil in Active comparator Arm if assymptomatic Cytomegalovirus viremia \>1000-\<5000 copies/mL observed
Study: NCT00043706
Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
Normalized name: transforming growth factor beta 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05516472
Drug: Microbial Transplant Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take microbial capsules, 2 capsules daily for 7 days
Study: NCT05516472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take placebo capsules
Study: NCT05322733
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 250mg/m2/day administered intravenously on Day 1-3 for every cycle (at most 6 cycles, 28-day cycles).
Study: NCT05485779
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral
Study: NCT05834478
Drug: [F-18]Fallypride
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[F-18\]Fallypride is a radioactive material. Each patient will have two \[F-18\]Fallypride PET scans. For each scan \[F-18\]Fallypride will be injected as an intravenous bolus. The radiation dose to body organs in this study is well within the Food and Drug Administration (FDA) national guidelines for radiation exposure for human research studies and less than the total amount that is permitted for research studies in one year.
Study: NCT04695080
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered as weight adjusted tablets in two treatment courses (12 months apart) lasting 8-10 days each.~Placebo 10mg available in blister packs of 1 tablet, 4 tablets and 6 tablets.
Study: NCT06104319
Drug: GSK4532990
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK4532990 will be administered
Study: NCT06342986
Drug: CY
Normalized name: CYT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CY 300 mg/m2 IV given on day -4. Given consecutively with Fludarabine.
Study: NCT06560684
Drug: TFV rectal douche
Approvals — FDA: no, EMA: no, PMDA: no
Description: For 8 weeks of each study period, the participant will take the study product at least weekly prior to anticipated rectal anal intercourse (RAI).
Study: NCT06157255
Drug: AZD4604 Inhalation Powder, 1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg dose, inhaled, fasted
Study: NCT06157255
Drug: [14C]AZD4604 Solution for Infusion 6 μg/mL (NMT 37.0 kBq/5 mL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg, intravenous, fasted
Study: NCT06157255
Drug: [14C]AZD4604 Oral Solution, 4 mg (NMT 37.0 kBq)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg, oral, fasted
Study: NCT04937946
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl will be administered as an intravenous loading dose of 1 microgram/kg in 30 minutes, followed by a continuous intravenous infusion of 1μg/kg/hour. The infusion will be administered through a peripheral line. Fentanyl infusion will be initiated within 24 hours after the start of mechanical ventilation and will be continued until the end of mechanical ventilation, and not longer than 5 days .
Study: NCT06120491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT06559618
Drug: Phage Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 20 mL sterile solution containing one to three individual phage drug substances (TPC) with total strength (potency) 3 x 10\^8 plaque-forming units (PFU), will be administered intravesicularly twice a day (one instillation in the morning and one in the evening \[at least six hours apart\], respectively) for 7 days. The selection of individual phages to include in the TPC are personalized/customized for each participant per phage susceptibility testing to the participant's urinary E. coli (testing is conducted by TAILФR Service Center). Each dose of TPC will be followed with a 10 mL flush of sterile 0.9% saline solution.
Study: NCT05741060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 10 mg per day for 24 months of tablets that will be the same size/shape/color as the s-equol tablets.
Study: NCT04263831
Drug: Interleukin-2 (aldesleukin).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Description of intervention is covered in Arm, above.
Study: NCT05047185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules for oral use
Study: NCT03937830
Drug: Doxorubicin-Eluting Beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: used for TACE (only in patients with HCC BCLC stage B)
Study: NCT03814109
Drug: LENINGRADO association
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 coated sustained-release tablet, oral, once a day.
Study: NCT03814109
Drug: Indapamide SR 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 coated sustained-release tablet, oral, once a day.
Study: NCT05939661
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles